Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 8:13:3157-3163.
doi: 10.2147/COPD.S172996. eCollection 2018.

Increased serum levels of S100A1, ZAG, and adiponectin in cachectic patients with COPD

Amin Mokari-Yamchi  1 , Akbar Sharifi  2 , Sorayya Kheirouri  1
Affiliations

Increased serum levels of S100A1, ZAG, and adiponectin in cachectic patients with COPD

Amin Mokari-Yamchi et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Background: COPD is a common irreversible obstructive airway disease. S100A1, ZAG, and adiponectin are important regulators of energy metabolism and body weight. Therefore, the aim of this study was to assess resting metabolic rate (RMR) and its association with serum levels of S100A1, ZAG, and adiponectin in cachectic and noncachectic COPD patients.

Patients and methods: Ninety men with COPD, aged 40-70 years, were enrolled in the study. Patients were divided into the following two groups based on the unintentional weight loss of .7.5% in previous 6 months: noncachectic (n=45) and cachectic (n=45). The groups were matched based on age and body mass index (BMI). RMR was measured by indirect calorimetry method. Anthropometric indices and body composition were also measured. Serum levels of S100A1, ZAG, and adiponectin were measured by ELISA.

Results: Cachectic patients had significantly higher RMR than controls (P<0.001). Serum levels of ZAG, S100A1, and adiponectin were significantly higher in the cachexia group (P<0.0001). RMR was not significantly associated with S100A1, ZAG, and adiponectin levels. However, weight loss of patients was significantly associated with serum levels of ZAG and adiponectin (both, β=0.22, P=0.03). Strong and positive association were found between the serum levels of S100A1 and ZAG (β=0.88, P<0.0001), S100A1 and adiponectin (β=0.86, P<0.0001), and also ZAG and adiponectin (β=0.83, P<0.0001).

Conclusion: The potential role of these factors in the wasting process is considerable. Also, the association between serum levels of S100A1, ZAG, and adiponectin represents that these three proteins are probably related to specific functions.

Keywords: COPD; RMR; S100A1; ZAG; adiponectin; cachexia.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
RMR (A) and serum levels of S100A1 (B), ZAG (C), and adiponectin (D) in cachectic and noncachectic groups. Notes: Data are presented as mean ± SD. P-values are reported based on ANCOVA after controlling the physical activity and RMR. Abbreviations: RMR, resting metabolic rate; ZAG, zinc alpha 2-glycoprotein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. - PubMed
    1. Ko FW, Cheung NK, Rainer TH, Lum C, Wong I, Hui DS. Comprehensive care programme for patients with chronic obstructive pulmonary disease: a randomised controlled trial. Thorax. 2017;72(2):122–128. - PubMed
    1. World Health Organization Global Burden of Disease Study [homepage on the Internet] [Accessed November 26, 2017]. Available from: http://www.who.int/respiratory/copd/burden/en/
    1. Kim YS. Definition and epidemiology of COPD. In: Lee SD, editor. COPD. Berlin: Springer; 2017. pp. 3–7.
    1. Huertas A, Palange P. COPD: a multifactorial systemic disease. Ther Adv Respir Dis. 2011;5(3):217–224. - PubMed

MeSH terms